Rotavirus Vaccine: Current Use and Future Considerations

  title={Rotavirus Vaccine: Current Use and Future Considerations},
  author={Patricia Cj Bruijning-Verhagen and Michelle J. Groome},
  journal={The Pediatric Infectious Disease Journal},
2 Citations
Establishment of a cell-based RT-qPCR assay for detection of multivalent rotavirus vaccine.
This one-step TaqMan probe-based quantitative RT-qPCR assay combined with cell-based method is a more rapid, cost-effective and high-throughput way for detecting multivalent rotavirus vaccine, and will be a valuable tool in the quality control and stability monitoring of live multivalent rotate virus vaccine. Expand
Establishment of a cell‐based quantitative reverse transcription‐polymerase chain reaction (RT‐qPCR) assay for detection of multivalent rotavirus vaccine
Because of deficiencies of traditional potency tests in rotavirus detection, a one‐step TaqMan probe‐based quantitative reverse transcription‐polymerase chain reaction (RT‐qPCR) assay combined withExpand


Health Impact of Rotavirus Vaccination in Developing Countries: Progress and Way Forward.
The data highlight the benefits of vaccination and should provide valuable evidence to sustain vaccine use in developing countries and encourage other countries to adopt routine rotavirus vaccination to reduce the health burden of severe childhood gastroenteritis. Expand
Rotavirus vaccination and intussusception – Science, surveillance, and safety: A review of evidence and recommendations for future research priorities in low and middle income countries
Evaluating updated data and meeting participants agreed with statements from expert bodies that the benefits of vaccination with currently available rotavirus vaccines outweigh the low risk of vaccination-associated intussusception, but further research is needed to better understand the relationship of intussUSception to wild-type rotvirus and rotav virus vaccines. Expand
Universal Mass Vaccination Against Rotavirus: Indirect Effects on Rotavirus Infections in Neonates and Unvaccinated Young Infants Not Eligible for Vaccination.
Unvaccinated neonates and infants ≤42 days old may indirectly benefit from UMV by reduction of RV infections, underline the importance of early and complete protection by the vaccine. Expand
Vaccines and me
My work with LAC showed that unlike rhabdo and paramyxo viruses, LAC, a bunya virus, utilized a remarkably similar transcription and replication pattern to the recently described cap-snatching mechanism of initiating transcription of influenza viruses. Expand
Effectiveness and impact of rotavirus vaccines in Europe, 2006-2014.
Across Europe, vaccine effectiveness against rotavirus-related healthcare utilisation ranged from 68% to 98%, consistent with efficacy data from clinical trials and with findings from post-marketing studies from the US and Latin America. Expand
Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial.
RV3-BB vaccine was immunogenic and well tolerated when given as a three-dose neonatal or infant schedule and was not associated with an increased frequency of fever or gastrointestinal symptoms compared with placebo. Expand
Effectiveness and impact of rotavirus vaccines in the United States – 2006–2012
Substantial decreases in severe diarrheal disease in US children, exceeding the level expected based on vaccine coverage, as well as the extension of benefits to older age groups ineligible for vaccination have demonstrated both the direct and indirect impacts of vaccination in the USA. Expand
Nosocomial rotavirus gastroenteritis in a Canadian paediatric hospital: incidence, disease burden and patients affected.
Nosocomial rotavirus infection continues to be an important problem in paediatric hospitals, predominantly for children with underlying medical conditions requiring recurrent and prolonged hospitalisation, and requires assessment in Canada and other countries that have not introduced universal rotav virus immunisation. Expand
Rotavirus shedding in premature infants following first immunization.
It is demonstrated that premature infants have positive stools by EIA, viral culture, and RT-PCR at varying time points during 2 weeks following first-dose immunization with RV5, supporting low transmissibility of vaccine virus shed by these infants born prematurely. Expand
Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa
Three doses of RIX4414 vaccine was tolerated well by the South African HIV-positive infants and a satisfactory immune response was mounted without aggravating their immunologic or HIV condition. Expand